These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 33522416)
1. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Ji S; Lee J; Lee ES; Kim DH; Sin JI Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416 [TBL] [Abstract][Full Text] [Related]
2. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714 [TBL] [Abstract][Full Text] [Related]
3. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901 [TBL] [Abstract][Full Text] [Related]
4. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352 [TBL] [Abstract][Full Text] [Related]
5. An Immunomodulatory Gallotanin-Rich Fraction From Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S Front Immunol; 2020; 11():584959. PubMed ID: 33312174 [TBL] [Abstract][Full Text] [Related]
6. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8 Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728 [No Abstract] [Full Text] [Related]
7. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1. Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811 [TBL] [Abstract][Full Text] [Related]
8. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice. Hu Z; Ye L; Xing Y; Hu J; Xi T Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734 [TBL] [Abstract][Full Text] [Related]
9. NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. Iraolagoitia XL; Spallanzani RG; Torres NI; Araya RE; Ziblat A; Domaica CI; Sierra JM; Nuñez SY; Secchiari F; Gajewski TF; Zwirner NW; Fuertes MB J Immunol; 2016 Aug; 197(3):953-61. PubMed ID: 27342842 [TBL] [Abstract][Full Text] [Related]
10. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Durgan K; Ali M; Warner P; Latchman YE Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487 [TBL] [Abstract][Full Text] [Related]
11. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy. Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259 [TBL] [Abstract][Full Text] [Related]
12. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M Front Immunol; 2022; 13():794684. PubMed ID: 35720386 [TBL] [Abstract][Full Text] [Related]
13. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Sin JI; Park JB; Lee IH; Park D; Choi YS; Choe J; Celis E Cancer Immunol Immunother; 2012 Oct; 61(10):1671-82. PubMed ID: 22382361 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476 [TBL] [Abstract][Full Text] [Related]
15. The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells. Cho J; Tae N; Song Y; Kim CW; Lee SJ; Ahn JH; Lee KH; Lee BH; Kim BS; Chang SY; Kim DH; Ko HJ Cancer Immunol Immunother; 2024 Aug; 73(10):196. PubMed ID: 39105814 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149 [TBL] [Abstract][Full Text] [Related]
17. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS Front Immunol; 2020; 11():7. PubMed ID: 32117218 [TBL] [Abstract][Full Text] [Related]
18. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression. Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH Cells; 2020 Nov; 9(11):. PubMed ID: 33171765 [TBL] [Abstract][Full Text] [Related]
19. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model. Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587 [TBL] [Abstract][Full Text] [Related]
20. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Nagato T; Lee YR; Harabuchi Y; Celis E Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]